Clinical Home Page Slider 2014

Clinical oversight for injured workers to prevent abuse



Ancillary Benefits Management for Workers’ Compensation


Mobile app for workers compensation

About Us

myMatrixx provides pharmacy and ancillary services for workers’ compensation programs. Our services control costs with proactive clinical oversight throughout the claims process. With one online tool also available in a mobile app, clients can manage claims with real time data and detailed reporting.

Learn more

The Latest


myMatrixx Recognized with “Fast 50” Award

Posted by On July 28, 2015

myMatrixx Recognized with “Fast 50” Award Tampa, FL, July 28, 2015 – myMatrixx, a pharmacy and ancillary medical benefit manager for workers’ compensation, announced today that the Tampa Bay Business Journal has named myMatrixx to their annual “Fast 50” list of the fastest growing privately-held companies in the Tampa Bay area. The company’s impressive $37 million growth (50.77%) over […]

myMatrixx is pleased to announce a new benefit for our clients: “FaceTime with Phil.”

Posted by On June 18, 2015

Phil Walls, our Chief Clinical Officer, is a clinical pharmacist with over 25 years of experience. He is a nationally recognized speaker, author, and a forward-thinking leader who has implemented groundbreaking clinical programs currently in use by the largest workers’ compensation carriers in the nation. We would like to offer the opportunity for your team […]


New “N” Drug Classifications in Texas and Oklahoma: Essential Information for Claims Professionals

Posted by On November 09, 2015

by Phil Walls, myMatrixx Chief Clinical Officer The Texas Department of Insurance Division of Workers’ Compensation has announced that both Duragesic® (fentanyl) transdermal system patches and MS Contin® (morphine sulfate) extended-release tablets will be classified as “N” Drugs, effective February 1, 2016.  These drugs belong to a drug class known as long-acting opioids, which also […]

Drug of the Month: Relistor® A Step-Therapy Approach to Opioid-Induced Constipation

Posted by On November 02, 2015

By: Rachel Crowe, PharmD Candidate 2016 Alan Rook, PharmD 1. What is Relistor®? Relistor® (methylnaltrexone bromide), manufactured by Valeant Pharmaceuticals International, Inc., is FDA approved for opioid-induced constipation in patients with chronic non-cancer pain as well as opioid-induced constipation with advanced illness. Opioid analgesics are able to cross the blood brain barrier (BBB) and act […]

Visit Blog


View All